Rituximab biosimilar - Adello Biologics

Drug Profile

Rituximab biosimilar - Adello Biologics

Latest Information Update: 21 Nov 2016

Price : $50

At a glance

  • Originator Therapeutic Proteins International
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Autoimmune disorders; Cancer; Transplant rejection

Most Recent Events

  • 16 Nov 2016 Therapeutic Proteins International is now called Adello Biologics
  • 24 Jun 2015 Discontinued for Autoimmune disorders in USA (unspecified route)
  • 24 Jun 2015 Discontinued for Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top